Medicare, Medicaid, and CLIA Programs; Clinical Laboratory Improvement Amendments of 1988 Exemption of Laboratories Licensed by the State of Washington, 51591-51594 [2019-21062]

Download as PDF Federal Register / Vol. 84, No. 189 / Monday, September 30, 2019 / Notices khammond on DSKJM1Z7X2PROD with NOTICES invited to send comments regarding our burden estimates or any other aspect of this collection of information, including the necessity and utility of the proposed information collection for the proper performance of the agency’s functions, the accuracy of the estimated burden, ways to enhance the quality, utility, and clarity of the information to be collected, and the use of automated collection techniques or other forms of information technology to minimize the information collection burden. DATES: Comments must be received by November 29, 2019. ADDRESSES: When commenting, please reference the document identifier or OMB control number. To be assured consideration, comments and recommendations must be submitted in any one of the following ways: 1. Electronically. You may send your comments electronically to https:// www.regulations.gov. Follow the instructions for ‘‘Comment or Submission’’ or ‘‘More Search Options’’ to find the information collection document(s) that are accepting comments. 2. By regular mail. You may mail written comments to the following address: CMS, Office of Strategic Operations and Regulatory Affairs, Division of Regulations Development, Attention: Document Identifier/OMB Control Number l, Room C4–26–05, 7500 Security Boulevard, Baltimore, Maryland 21244–1850. To obtain copies of a supporting statement and any related forms for the proposed collection(s) summarized in this notice, you may make your request using one of following: 1. Access CMS’ website address at website address at https://www.cms.gov/ Regulations-and-Guidance/Legislation/ PaperworkReductionActof1995/PRAListing.html. 2. Email your request, including your address, phone number, OMB number, and CMS document identifier, to Paperwork@cms.hhs.gov. 3. Call the Reports Clearance Office at (410) 786–1326. FOR FURTHER INFORMATION CONTACT: William N. Parham at (410) 786–4669. SUPPLEMENTARY INFORMATION: Contents This notice sets out a summary of the use and burden associated with the following information collections. More detailed information can be found in each collection’s supporting statement and associated materials (see ADDRESSES). VerDate Sep<11>2014 19:16 Sep 27, 2019 Jkt 247001 CMS–10709 Hospital Survey for Specified Covered Outpatient Drugs (SCODs) Under the PRA (44 U.S.C. 3501– 3520), federal agencies must obtain approval from the Office of Management and Budget (OMB) for each collection of information they conduct or sponsor. The term ‘‘collection of information’’ is defined in 44 U.S.C. 3502(3) and 5 CFR 1320.3(c) and includes agency requests or requirements that members of the public submit reports, keep records, or provide information to a third party. Section 3506(c)(2)(A) of the PRA requires federal agencies to publish a 60-day notice in the Federal Register concerning each proposed collection of information, including each proposed extension or reinstatement of an existing collection of information, before submitting the collection to OMB for approval. To comply with this requirement, CMS is publishing this notice. Information Collection 1. Type of Information Collection Request: New collection (Request for a new OMB control number); Title of Information Collection: Hospital Survey for Specified Covered Outpatient Drugs (SCODs); Use: In the CY 2018 OPPS/ ASC payment system final rule with comment period, CMS finalized a policy to adjust payment for separately payable outpatient drugs acquired by eligible hospitals at discounted rates under HRSA’s 340B program from Average Sales Price (ASP) plus 6 percent to ASP minus 22.5 percent. According to 42 U.S.C. 256b, eligible hospitals include those with a Medicare Disproportionate Share Hospital adjustment of greater than 11.75 percent, Children’s Hospitals, Critical Access Hospitals, Cancer Hospitals, Rural Referral Centers and Sole Community Hospitals. The 340B program sets a ceiling on the price that covered entities pay for outpatient drugs. The 340B ceiling price refers to the maximum amount that a manufacturer can charge a covered entity for the purchase of a 340B covered outpatient drug. The 340B ceiling price is statutorily defined as the Average Manufacturer Price (AMP) reduced by the rebate percentage, which is commonly referred to as the Unit Rebate Amount (URA). On December 27, 2018, the United States District Court for the District of Columbia ruled that the Secretary of the Department of Health & Human Services exceeded his statutory authority to adjust payment rates under the Hospital Outpatient Prospective Payment System (OPPS) for separately payable, 340B- PO 00000 Frm 00084 Fmt 4703 Sfmt 4703 51591 acquired drugs. See American Hospital Ass’n v. Azar, 348 F. Supp. 3d 62, 82– 83 (D.D.C. 2018), appeal pending, Nos. 19–5048 & 19–5198 (D.C. Cir.). The Court reasoned, in part, that the Secretary had not collected the necessary data to set payment rates based on acquisition costs. The government disagrees with that ruling and has appealed. Nonetheless, in the event that the ruling is affirmed, CMS believes that it is important to begin obtaining acquisition costs for specified covered outpatient drugs to set payment rates based on cost for 340B-acquired drugs when they are furnished by certain covered entity hospitals. The acquisition cost data hospitals submit in response to this survey will be used to help determine payment amounts for drugs acquired under the 340B program. We want to ensure that the Medicare program pays for specified covered outpatient drugs purchased under the 340B program at amounts that approximate what hospitals actually pay to acquire the drugs. This will ensure that the Medicare program uses taxpayer dollars prudently while maintaining beneficiary access to these drugs and allowing beneficiary cost-sharing to be based on the amounts hospitals actually pay to acquire the drugs. Form Number: CMS–10709 (OMB control number: 0938–New); Frequency: Occasionally; Affected Public: Business or other forprofits and Not-for-profits, State, Local, or Tribal Governments; Number of Respondents: 761; Total Annual Responses: 46,610,448; Total Annual Hours: 33,484. (For policy questions regarding this collection contact Steven Johnson at 410–786–3332.) Dated: September 25, 2019. William N. Parham, III, Director, Paperwork Reduction Staff, Office of Strategic Operations and Regulatory Affairs. [FR Doc. 2019–21120 Filed 9–26–19; 4:15 pm] BILLING CODE 4120–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Medicare & Medicaid Services [CMS–3383–N] Medicare, Medicaid, and CLIA Programs; Clinical Laboratory Improvement Amendments of 1988 Exemption of Laboratories Licensed by the State of Washington Centers for Medicare & Medicaid Services (CMS), HHS. ACTION: Notice. AGENCY: E:\FR\FM\30SEN1.SGM 30SEN1 51592 Federal Register / Vol. 84, No. 189 / Monday, September 30, 2019 / Notices This notice announces that laboratories located in and licensed by the State of Washington that possess a valid license under the Medical Test Site law, Chapter 70.42 of the Revised Code of Washington, are exempt from the requirements of the Clinical Laboratory Improvement Amendments of 1988 (CLIA) for a period of 4 years. DATES: The exemption takes effect on September 30, 2019 to October 2, 2023. FOR FURTHER INFORMATION CONTACT: Daniel Cajigas, (410) 786–0783. SUPPLEMENTARY INFORMATION: khammond on DSKJM1Z7X2PROD with NOTICES SUMMARY: I. Background and Legislative Authority Section 353 of the Public Health Service Act (PHSA), as amended by the Clinical Laboratory Improvement Amendments of 1988 (CLIA) (Pub. L. 100–578), which was enacted on October 31, 1988, generally provides that no laboratory may perform tests on human specimens for the diagnosis, prevention or treatment of any disease or impairment of, or assessment of the health of, human beings unless it has a certificate to perform that category of tests issued by the Secretary of the Department of Health and Human Services (HHS). Under section 1861(s)(17)(A) of the Social Security Act (the Act), the Medicare program will only pay for laboratory services if the laboratory has an appropriate CLIA certificate for the testing they conduct. Under section 1902(a)(9)(C) of the Act, state Medicaid plans will generally only pay for laboratory services furnished by CLIA-certified laboratories. Thus, although subject to specified exemptions and exceptions, laboratories generally must have a current and valid CLIA certificate to test human specimens for the purposes noted above to be eligible for payment for those tests by the Medicare or Medicaid programs. Regulations implementing section 353 of the PHSA are contained in 42 CFR part 493. Section 353(p) of the PHSA provides for the exemption of laboratories from CLIA requirements in states that enact legal requirements that are equal to or more stringent than CLIA’s statutory and regulatory requirements. Section 353(p) of the PHSA is implemented in subpart E of our regulations at 42 CFR part 493. Sections 493.551(b) and 493.553 provide that we may exempt from CLIA requirements, for a period not to exceed 6 years, all state-licensed or state-approved laboratories in a state if the state licensure program meets the specified conditions. Section 493.559 provides that we will publish a notice in the Federal Register when we grant VerDate Sep<11>2014 19:16 Sep 27, 2019 Jkt 247001 an exemption to an approved state licensure program. It also provides that the notice will include the following: • The basis for granting the exemption. • A description of how the laboratory requirements are equal to or more stringent than those of CLIA. • The term of approval, not to exceed 6 years. A. State of Washington’s Application for CLIA Exemption of Its Laboratories The State of Washington has applied for exemption of its laboratories from CLIA program requirements. The State of Washington submitted all of the applicable information and attestations required by §§ 493.551(a), 493.553, and 493.557(b) for state licensure programs seeking exemption of their licensed laboratories from CLIA program requirements. Examples of documents and information submitted include: A comparison of its laboratory licensure requirements with comparable CLIA condition-level requirements (that is, a crosswalk); and a description of the following: Its inspection process; its proficiency testing (PT) monitoring process; its data management and analysis system; its investigative and response procedures for complaints received against laboratories; and its policy regarding announced and unannounced inspections. B. CMS Analysis of Washington’s Application and Supporting Documentation To determine whether we should grant a CLIA exemption to laboratories licensed by a state, we review the application and additional documentation that the state submits to us and conduct a detailed and in-depth comparison of the state licensure program and CLIA’s statutory and regulatory requirements to determine whether the state program meets the requirements at subpart E of part 493. In summary, the state generally must demonstrate that: • It has state laws in effect that provide for a state licensure program that has requirements that are equal to or more stringent than CLIA conditionlevel requirements for laboratories. • It has implemented a state licensure program with requirements that are equal to or more stringent than the CLIA condition-level requirements such that a laboratory licensed by the state program would meet the CLIA condition-level requirements if it were inspected against those requirements. • The requirements under that state licensure program meet or exceed the requirements of §§ 493.553, 493.555, PO 00000 Frm 00085 Fmt 4703 Sfmt 4703 and 493.557(b) and are suitable for approval by us under § 493.551(a). For example, among other things, the program would need to: ++ Demonstrate that it has enforcement authority and administrative structures and resources adequate to enforce its laboratory requirements. ++ Permit us or our agents to inspect laboratories within the state. ++ Require laboratories within the state to submit to inspections by us or our agents as a condition of licensure. ++ Agree to pay any costs associated with our activities to validate its state licensure program as well as the state’s pro rata share of the general overhead to develop and implement CLIA as specified in §§ 493.645(a), 493.646(b), and 493.557(b). ++ Take appropriate enforcement action against laboratories found by us or our agents out of compliance with requirements comparable to CLIA condition-level requirements, as specified in § 493.557(b). As specified in our regulations at § 493.555 and § 493.557(b), our review of a state licensure program includes (but is not necessarily limited to) an evaluation of the following: • Whether the state’s requirements for laboratories are equal to or more stringent than the CLIA condition-level requirements. • The state’s inspection process requirements to determine the following: ++ The comparability of the full inspection and complaint inspection procedures to those of CMS. ++ The state’s enforcement procedures for laboratories found to be out of compliance with its requirements. • The ability of the state to provide us with electronic data and reports with the adverse or corrective actions resulting from PT results that constitute unsuccessful participation in CMSapproved PT programs and with other data we determine to be necessary for validation review and assessment of the state’s inspection process requirements. • The state’s agreement with us to ensure that the agreement obligates the state to do the following: ++ Notify us within 30 days of the action taken against any CLIA-exempt laboratory that has had its licensure or approval withdrawn or revoked or been in any way sanctioned. ++ Notify us within 10 days of any deficiency identified in a CLIA-exempt laboratory in cases when the deficiency poses an immediate jeopardy to the laboratory’s patients or a hazard to the general public. E:\FR\FM\30SEN1.SGM 30SEN1 khammond on DSKJM1Z7X2PROD with NOTICES Federal Register / Vol. 84, No. 189 / Monday, September 30, 2019 / Notices ++ Notify each laboratory licensed by the state under its approved state licensure program within 10 days of a withdrawal of our approval of the state’s licensure program, and the resulting loss of the laboratory’s exemption from CLIA based on its licensure under that program. ++ Provide us with written notification of any changes in the state’s licensure (or approval) and inspection requirements. ++ Disclose to us or our agent any laboratory’s PT results in accordance with the state’s confidentiality requirements. ++ Take appropriate enforcement action against laboratories that we or our agents find to be out of compliance with CLIA condition-level requirements in a validation survey, and report these enforcement actions to us. ++ Notify us of all newly licensed laboratories, and any changes in the specialties and subspecialties for which any laboratory performs testing, within 30 days. ++ Provide us, as requested, inspection schedules for validation purposes. In keeping with the process described above, we evaluated the application and supporting materials that were submitted by Washington State to verify that the laboratories licensed through its program will meet or exceed the requirements of the following subparts of part 493: Subpart H, Participation in Proficiency Testing for Laboratories Performing Nonwaived Testing; Subpart J, Facility Administration for Nonwaived Testing; Subpart K, Quality Systems for Nonwaived Testing, Subpart M, Personnel for Nonwaived Testing; Subpart Q, Inspection; and Subpart R, Enforcement Procedures. We found that Washington State’s laboratory licensure program requirements are equivalent to all the CLIA condition-level requirements. The state licensure program’s inspection process and PT monitoring processes were adequate. Other materials that were submitted demonstrated compliance with the other abovereferenced requirements of subpart E of part 493. As a result, we concluded that the submitted documents supported exempting laboratories licensed under that program from the CLIA program requirements. The federal validation inspections of CLIA-exempt laboratories, as specified in § 493.563, were conducted on a representative sample basis, as well as in response to any substantial allegations of noncompliance (complaint inspections). The outcome of those validation inspections has been, VerDate Sep<11>2014 19:16 Sep 27, 2019 Jkt 247001 and will continue to be our principal tool for verifying that the laboratories located in, and licensed by the state are in compliance with CLIA requirements. We have conducted validation inspections of a representative sample (approximately 5 percent) of the laboratories inspected by the Washington State Office of Laboratory Quality Assurance (LQA). The validation inspections were primarily of the concurrent type; that is, our surveyors accompanied Washington State’s inspectors, each inspecting against his or her agency’s respective regulations. Analysis of the validation data revealed no significant differences between the state and federal findings. The validation surveys verified that the State of Washington inspection process covers all CLIA conditions applicable to each laboratory being inspected and also verified that the state laboratory licensure requirements meet or exceed CLIA condition-level requirements. Our validation surveys found the state inspectors highly skilled and qualified. The LQA inspected laboratories in a timely fashion; that is, all laboratories were inspected within the required 24month cycle. All parameters monitored by our regional office in Seattle, Washington, to date, indicate that the State of Washington is meeting all requirements for approval of CLIA exemption. This federal monitoring will continue as an on-going process. C. Conclusion Based on review of the documents submitted by the Washington state licensure program under the requirements of subpart E of part 493, as well as the outcome of the validation inspections conducted by our regional office in Seattle, Washington, we find that the State of Washington’s licensure program meets the requirements of § 493.551(a), and that, as a result, we may exempt from CLIA program requirements all state-licensed laboratories. Approval of the CLIA exemption for laboratories located within and licensed by the State of Washington laboratory licensure program is subject to removal if we determine that the outcome of a comparability review or a validation review inspection is not acceptable, as described under §§ 493.573 and 493.575, or if the State of Washington fails to pay the required fee every 2 years as required under § 493.646(b). D. Laboratory Data In accordance with our regulations at § 493.557(b)(8), the approval of this exemption for laboratories located within and licensed by the State of PO 00000 Frm 00086 Fmt 4703 Sfmt 4703 51593 Washington is conditioned on the State of Washington’s continued compliance with the assertions made in its application, especially the provision of information to us about changes to a laboratory’s specialties or subspecialties based on the state’s survey, and changes to a laboratory’s certification status. E. Required Administrative Actions CLIA is a user-fee funded program. The registration fee paid by laboratories is intended to cover the cost of the development and administration of the program. However, when a state’s application for exemption is approved, we do not charge a fee to laboratories in the state. The state’s share of the costs associated with CLIA must be collected from the state, as specified in § 493.645(a). The State of Washington must pay for the following: • Costs of federal inspections of laboratories in the state to verify that Washington State’s laboratory licensure program requirements are equivalent to or more stringent than those in the CLIA program, and that they are enforced in an appropriate manner. The average federal hourly rate is multiplied by the total hours required to perform federal validation surveys within the state. • Costs incurred for federal surveys, including investigations of complaints that are substantiated. We will bill the State of Washington on a semiannual basis. • The State of Washington’s proportionate share of the costs associated with establishing, maintaining, and improving the CLIA computer system, based on the portion of those services from which the State of Washington received direct benefit or which contributed to the CLIA program in the state. Thus, the State of Washington is being charged for a portion of our direct and indirect costs of administering the CLIA program. Such costs will be incurred by CMS, the Centers for Disease Control and Prevention (CDC), the Food and Drug Administration (FDA) and contractors working on behalf of these respective agencies. To estimate the State of Washington’s proportionate share of the general overhead costs to develop and implement CLIA, we determined the ratio of laboratories in the state to the total number of laboratories nationally. Approximately 1.6 percent of the registered laboratories are in the State of Washington. We determined that a corresponding percentage of the applicable CMS, CDC, FDA, and their respective contractor costs should be borne by the State of Washington. E:\FR\FM\30SEN1.SGM 30SEN1 51594 Federal Register / Vol. 84, No. 189 / Monday, September 30, 2019 / Notices The State of Washington has agreed to pay the state’s pro rata share of the anticipated overhead costs and costs of actual validation (including complaint investigation surveys). A final reconciliation for all laboratories and all expenses will be made. We will reimburse the state for any overpayment or bill it for any balance. II. Approval In light of the foregoing, we grant approval of the State of Washington’s laboratory licensure program under subpart E. All laboratories located in and licensed by the State of Washington under the Medical Test Site law, Chapter 70.42 of the Revised Code of Washington, are CLIA-exempt for all specialties and subspecialties until October 2, 2023. III. Collection of Information Requirements This document does not impose information collection requirements, that is, reporting, recordkeeping or third-party disclosure requirements. Consequently, there is no need for review by the Office of Management and Budget under the authority of the Paperwork Reduction Act of 1995 (44 U.S.C. 3501 et seq.). Dated: September 12, 2019. Seema Verma, Administrator, Centers for Medicare & Medicaid Services. rating. In addition, the PRB will review and recommend executive performance bonuses and pay increases. 5 U.S.C. 4314(c)(4) requires the appointment of board members to be published in the Federal Register. The following persons comprise a standing roster to serve as members of the SES PRB for the Centers for Medicare & Medicaid Services: Jennifer Main, Chief Operating Officer (serves as the Chair) Kimberly Brandt, Principal Deputy Administrator for Policy and Operations Scott Giberson, Acting Director, Office of Human Capital Nancy O’Connor, Acting Consortium Administrator, Consortium for Medicare Health Plans Operations Randy Pate, Deputy Administrator and Director, Center for Consumer Information and Insurance Oversight Elizabeth Richter, Deputy Center Director, Center for Medicare Arrah Tabe-Bedward, Deputy Director, Center for Medicare and Medicaid Innovation Jeffrey, Deputy Director for Operations, Center for Consumer Information and Insurance Oversight Dated: September 5, 2019. Jennifer Main, Chief Operating Officer. [FR Doc. 2019–21061 Filed 9–27–19; 8:45 am] BILLING CODE 4120–01–P [FR Doc. 2019–21062 Filed 9–27–19; 8:45 am] BILLING CODE 4120–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. FDA–2019–D–3361] Centers for Medicare & Medicaid Services Eligibility Criteria for Expanded Conditional Approval of New Animal Drugs; Draft Guidance for Industry; Availability Performance Review Board Membership Centers for Medicare & Medicaid Services, HHS. ACTION: Notice of Performance Review Board Membership. AGENCY: khammond on DSKJM1Z7X2PROD with NOTICES FOR FURTHER INFORMATION CONTACT: Kathy Vaughn, 410–786–1050 or katherine.vaughn@cms.hhs.gov. 5 U.S.C. 4314(c)(1) through (5) requires each agency to establish, in accordance with regulations prescribed by the Office of Personnel Management, one or more Senior Executive Service (SES) Performance Review Boards. The PRB shall review and evaluate the initial summary rating of a senior executive’s performance, the executive’s response, and the higher-level official’s comments on the initial summary VerDate Sep<11>2014 19:16 Sep 27, 2019 Jkt 247001 AGENCY: Food and Drug Administration, HHS. ACTION: Notice of availability. The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry (GFI) #261 entitled ‘‘Eligibility Criteria for Expanded Conditional Approval of New Animal Drugs.’’ This draft guidance is intended for persons interested in pursuing conditional approval of new animal drugs for certain major uses in major species. Eligibility for conditional approval has been expanded beyond minor uses in major species and minor species to include certain major uses. The Center for Veterinary Medicine SUMMARY: PO 00000 Frm 00087 Fmt 4703 Sfmt 4703 (CVM) refers to the process for conditionally approving new animal drugs that are not minor use and minor species (MUMS) drugs as ‘‘expanded conditional approval.’’ The purpose of expanded conditional approval is to incentivize development of new animal drugs for serious or life-threatening conditions or unmet animal or human health needs under circumstances where a demonstration of effectiveness would require a complex or particularly difficult study or studies. This draft guidance defines certain terms, clarifies the eligibility criteria for expanded conditional approval, and describes the criteria CVM intends to consider when determining expanded conditional approval eligibility. DATES: Submit either electronic or written comments on the draft guidance by January 28, 2020 to ensure that the Agency considers your comment on this draft guidance before it begins work on the final version of the guidance. ADDRESSES: You may submit comments on any guidance at any time as follows: Electronic Submissions Submit electronic comments in the following way: • Federal eRulemaking Portal: https://www.regulations.gov. Follow the instructions for submitting comments. Comments submitted electronically, including attachments, to https:// www.regulations.gov will be posted to the docket unchanged. Because your comment will be made public, you are solely responsible for ensuring that your comment does not include any confidential information that you or a third party may not wish to be posted, such as medical information, your or anyone else’s Social Security number, or confidential business information, such as a manufacturing process. Please note that if you include your name, contact information, or other information that identifies you in the body of your comments, that information will be posted on https://www.regulations.gov. • If you want to submit a comment with confidential information that you do not wish to be made available to the public, submit the comment as a written/paper submission and in the manner detailed (see ‘‘Written/Paper Submissions’’ and ‘‘Instructions’’). Written/Paper Submissions Submit written/paper submissions as follows: • Mail/Hand Delivery/Courier (for written/paper submissions): Dockets Management Staff (HFA–305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852. E:\FR\FM\30SEN1.SGM 30SEN1

Agencies

[Federal Register Volume 84, Number 189 (Monday, September 30, 2019)]
[Notices]
[Pages 51591-51594]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-21062]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Medicare & Medicaid Services

[CMS-3383-N]


Medicare, Medicaid, and CLIA Programs; Clinical Laboratory 
Improvement Amendments of 1988 Exemption of Laboratories Licensed by 
the State of Washington

AGENCY: Centers for Medicare & Medicaid Services (CMS), HHS.

ACTION: Notice.

-----------------------------------------------------------------------

[[Page 51592]]

SUMMARY: This notice announces that laboratories located in and 
licensed by the State of Washington that possess a valid license under 
the Medical Test Site law, Chapter 70.42 of the Revised Code of 
Washington, are exempt from the requirements of the Clinical Laboratory 
Improvement Amendments of 1988 (CLIA) for a period of 4 years.

DATES: The exemption takes effect on September 30, 2019 to October 2, 
2023.

FOR FURTHER INFORMATION CONTACT: Daniel Cajigas, (410) 786-0783.

SUPPLEMENTARY INFORMATION:

I. Background and Legislative Authority

    Section 353 of the Public Health Service Act (PHSA), as amended by 
the Clinical Laboratory Improvement Amendments of 1988 (CLIA) (Pub. L. 
100-578), which was enacted on October 31, 1988, generally provides 
that no laboratory may perform tests on human specimens for the 
diagnosis, prevention or treatment of any disease or impairment of, or 
assessment of the health of, human beings unless it has a certificate 
to perform that category of tests issued by the Secretary of the 
Department of Health and Human Services (HHS). Under section 
1861(s)(17)(A) of the Social Security Act (the Act), the Medicare 
program will only pay for laboratory services if the laboratory has an 
appropriate CLIA certificate for the testing they conduct. Under 
section 1902(a)(9)(C) of the Act, state Medicaid plans will generally 
only pay for laboratory services furnished by CLIA-certified 
laboratories. Thus, although subject to specified exemptions and 
exceptions, laboratories generally must have a current and valid CLIA 
certificate to test human specimens for the purposes noted above to be 
eligible for payment for those tests by the Medicare or Medicaid 
programs. Regulations implementing section 353 of the PHSA are 
contained in 42 CFR part 493.
    Section 353(p) of the PHSA provides for the exemption of 
laboratories from CLIA requirements in states that enact legal 
requirements that are equal to or more stringent than CLIA's statutory 
and regulatory requirements. Section 353(p) of the PHSA is implemented 
in subpart E of our regulations at 42 CFR part 493. Sections 493.551(b) 
and 493.553 provide that we may exempt from CLIA requirements, for a 
period not to exceed 6 years, all state-licensed or state-approved 
laboratories in a state if the state licensure program meets the 
specified conditions. Section 493.559 provides that we will publish a 
notice in the Federal Register when we grant an exemption to an 
approved state licensure program. It also provides that the notice will 
include the following:
     The basis for granting the exemption.
     A description of how the laboratory requirements are equal 
to or more stringent than those of CLIA.
     The term of approval, not to exceed 6 years.

A. State of Washington's Application for CLIA Exemption of Its 
Laboratories

    The State of Washington has applied for exemption of its 
laboratories from CLIA program requirements. The State of Washington 
submitted all of the applicable information and attestations required 
by Sec. Sec.  493.551(a), 493.553, and 493.557(b) for state licensure 
programs seeking exemption of their licensed laboratories from CLIA 
program requirements. Examples of documents and information submitted 
include: A comparison of its laboratory licensure requirements with 
comparable CLIA condition-level requirements (that is, a crosswalk); 
and a description of the following: Its inspection process; its 
proficiency testing (PT) monitoring process; its data management and 
analysis system; its investigative and response procedures for 
complaints received against laboratories; and its policy regarding 
announced and unannounced inspections.

B. CMS Analysis of Washington's Application and Supporting 
Documentation

    To determine whether we should grant a CLIA exemption to 
laboratories licensed by a state, we review the application and 
additional documentation that the state submits to us and conduct a 
detailed and in-depth comparison of the state licensure program and 
CLIA's statutory and regulatory requirements to determine whether the 
state program meets the requirements at subpart E of part 493.
    In summary, the state generally must demonstrate that:
     It has state laws in effect that provide for a state 
licensure program that has requirements that are equal to or more 
stringent than CLIA condition-level requirements for laboratories.
     It has implemented a state licensure program with 
requirements that are equal to or more stringent than the CLIA 
condition-level requirements such that a laboratory licensed by the 
state program would meet the CLIA condition-level requirements if it 
were inspected against those requirements.
     The requirements under that state licensure program meet 
or exceed the requirements of Sec. Sec.  493.553, 493.555, and 
493.557(b) and are suitable for approval by us under Sec.  493.551(a). 
For example, among other things, the program would need to:
    ++ Demonstrate that it has enforcement authority and administrative 
structures and resources adequate to enforce its laboratory 
requirements.
    ++ Permit us or our agents to inspect laboratories within the 
state.
    ++ Require laboratories within the state to submit to inspections 
by us or our agents as a condition of licensure.
    ++ Agree to pay any costs associated with our activities to 
validate its state licensure program as well as the state's pro rata 
share of the general overhead to develop and implement CLIA as 
specified in Sec. Sec.  493.645(a), 493.646(b), and 493.557(b).
    ++ Take appropriate enforcement action against laboratories found 
by us or our agents out of compliance with requirements comparable to 
CLIA condition-level requirements, as specified in Sec.  493.557(b).
    As specified in our regulations at Sec.  493.555 and Sec.  
493.557(b), our review of a state licensure program includes (but is 
not necessarily limited to) an evaluation of the following:
     Whether the state's requirements for laboratories are 
equal to or more stringent than the CLIA condition-level requirements.
     The state's inspection process requirements to determine 
the following:
    ++ The comparability of the full inspection and complaint 
inspection procedures to those of CMS.
    ++ The state's enforcement procedures for laboratories found to be 
out of compliance with its requirements.
     The ability of the state to provide us with electronic 
data and reports with the adverse or corrective actions resulting from 
PT results that constitute unsuccessful participation in CMS-approved 
PT programs and with other data we determine to be necessary for 
validation review and assessment of the state's inspection process 
requirements.
     The state's agreement with us to ensure that the agreement 
obligates the state to do the following:
    ++ Notify us within 30 days of the action taken against any CLIA-
exempt laboratory that has had its licensure or approval withdrawn or 
revoked or been in any way sanctioned.
    ++ Notify us within 10 days of any deficiency identified in a CLIA-
exempt laboratory in cases when the deficiency poses an immediate 
jeopardy to the laboratory's patients or a hazard to the general 
public.

[[Page 51593]]

    ++ Notify each laboratory licensed by the state under its approved 
state licensure program within 10 days of a withdrawal of our approval 
of the state's licensure program, and the resulting loss of the 
laboratory's exemption from CLIA based on its licensure under that 
program.
    ++ Provide us with written notification of any changes in the 
state's licensure (or approval) and inspection requirements.
    ++ Disclose to us or our agent any laboratory's PT results in 
accordance with the state's confidentiality requirements.
    ++ Take appropriate enforcement action against laboratories that we 
or our agents find to be out of compliance with CLIA condition-level 
requirements in a validation survey, and report these enforcement 
actions to us.
    ++ Notify us of all newly licensed laboratories, and any changes in 
the specialties and subspecialties for which any laboratory performs 
testing, within 30 days.
    ++ Provide us, as requested, inspection schedules for validation 
purposes.
    In keeping with the process described above, we evaluated the 
application and supporting materials that were submitted by Washington 
State to verify that the laboratories licensed through its program will 
meet or exceed the requirements of the following subparts of part 493: 
Subpart H, Participation in Proficiency Testing for Laboratories 
Performing Nonwaived Testing; Subpart J, Facility Administration for 
Nonwaived Testing; Subpart K, Quality Systems for Nonwaived Testing, 
Subpart M, Personnel for Nonwaived Testing; Subpart Q, Inspection; and 
Subpart R, Enforcement Procedures.
    We found that Washington State's laboratory licensure program 
requirements are equivalent to all the CLIA condition-level 
requirements. The state licensure program's inspection process and PT 
monitoring processes were adequate. Other materials that were submitted 
demonstrated compliance with the other above-referenced requirements of 
subpart E of part 493. As a result, we concluded that the submitted 
documents supported exempting laboratories licensed under that program 
from the CLIA program requirements.
    The federal validation inspections of CLIA-exempt laboratories, as 
specified in Sec.  493.563, were conducted on a representative sample 
basis, as well as in response to any substantial allegations of 
noncompliance (complaint inspections). The outcome of those validation 
inspections has been, and will continue to be our principal tool for 
verifying that the laboratories located in, and licensed by the state 
are in compliance with CLIA requirements.
    We have conducted validation inspections of a representative sample 
(approximately 5 percent) of the laboratories inspected by the 
Washington State Office of Laboratory Quality Assurance (LQA). The 
validation inspections were primarily of the concurrent type; that is, 
our surveyors accompanied Washington State's inspectors, each 
inspecting against his or her agency's respective regulations. Analysis 
of the validation data revealed no significant differences between the 
state and federal findings. The validation surveys verified that the 
State of Washington inspection process covers all CLIA conditions 
applicable to each laboratory being inspected and also verified that 
the state laboratory licensure requirements meet or exceed CLIA 
condition-level requirements. Our validation surveys found the state 
inspectors highly skilled and qualified. The LQA inspected laboratories 
in a timely fashion; that is, all laboratories were inspected within 
the required 24-month cycle. All parameters monitored by our regional 
office in Seattle, Washington, to date, indicate that the State of 
Washington is meeting all requirements for approval of CLIA exemption. 
This federal monitoring will continue as an on-going process.

C. Conclusion

    Based on review of the documents submitted by the Washington state 
licensure program under the requirements of subpart E of part 493, as 
well as the outcome of the validation inspections conducted by our 
regional office in Seattle, Washington, we find that the State of 
Washington's licensure program meets the requirements of Sec.  
493.551(a), and that, as a result, we may exempt from CLIA program 
requirements all state-licensed laboratories.
    Approval of the CLIA exemption for laboratories located within and 
licensed by the State of Washington laboratory licensure program is 
subject to removal if we determine that the outcome of a comparability 
review or a validation review inspection is not acceptable, as 
described under Sec. Sec.  493.573 and 493.575, or if the State of 
Washington fails to pay the required fee every 2 years as required 
under Sec.  493.646(b).

D. Laboratory Data

    In accordance with our regulations at Sec.  493.557(b)(8), the 
approval of this exemption for laboratories located within and licensed 
by the State of Washington is conditioned on the State of Washington's 
continued compliance with the assertions made in its application, 
especially the provision of information to us about changes to a 
laboratory's specialties or subspecialties based on the state's survey, 
and changes to a laboratory's certification status.

E. Required Administrative Actions

    CLIA is a user-fee funded program. The registration fee paid by 
laboratories is intended to cover the cost of the development and 
administration of the program. However, when a state's application for 
exemption is approved, we do not charge a fee to laboratories in the 
state. The state's share of the costs associated with CLIA must be 
collected from the state, as specified in Sec.  493.645(a).
    The State of Washington must pay for the following:
     Costs of federal inspections of laboratories in the state 
to verify that Washington State's laboratory licensure program 
requirements are equivalent to or more stringent than those in the CLIA 
program, and that they are enforced in an appropriate manner. The 
average federal hourly rate is multiplied by the total hours required 
to perform federal validation surveys within the state.
     Costs incurred for federal surveys, including 
investigations of complaints that are substantiated. We will bill the 
State of Washington on a semiannual basis.
     The State of Washington's proportionate share of the costs 
associated with establishing, maintaining, and improving the CLIA 
computer system, based on the portion of those services from which the 
State of Washington received direct benefit or which contributed to the 
CLIA program in the state. Thus, the State of Washington is being 
charged for a portion of our direct and indirect costs of administering 
the CLIA program. Such costs will be incurred by CMS, the Centers for 
Disease Control and Prevention (CDC), the Food and Drug Administration 
(FDA) and contractors working on behalf of these respective agencies.
    To estimate the State of Washington's proportionate share of the 
general overhead costs to develop and implement CLIA, we determined the 
ratio of laboratories in the state to the total number of laboratories 
nationally. Approximately 1.6 percent of the registered laboratories 
are in the State of Washington. We determined that a corresponding 
percentage of the applicable CMS, CDC, FDA, and their respective 
contractor costs should be borne by the State of Washington.

[[Page 51594]]

    The State of Washington has agreed to pay the state's pro rata 
share of the anticipated overhead costs and costs of actual validation 
(including complaint investigation surveys). A final reconciliation for 
all laboratories and all expenses will be made. We will reimburse the 
state for any overpayment or bill it for any balance.

II. Approval

    In light of the foregoing, we grant approval of the State of 
Washington's laboratory licensure program under subpart E. All 
laboratories located in and licensed by the State of Washington under 
the Medical Test Site law, Chapter 70.42 of the Revised Code of 
Washington, are CLIA-exempt for all specialties and subspecialties 
until October 2, 2023.

III. Collection of Information Requirements

    This document does not impose information collection requirements, 
that is, reporting, recordkeeping or third-party disclosure 
requirements. Consequently, there is no need for review by the Office 
of Management and Budget under the authority of the Paperwork Reduction 
Act of 1995 (44 U.S.C. 3501 et seq.).

    Dated: September 12, 2019.
Seema Verma,
Administrator, Centers for Medicare & Medicaid Services.
[FR Doc. 2019-21062 Filed 9-27-19; 8:45 am]
BILLING CODE 4120-01-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.